Table 1.
Baseline patient features
| Regimen 1 (n = 32) | Regimen 2 (n = 33) | Regimen 3 (n = 33) | All regimens (n = 98) | |
|---|---|---|---|---|
| Age (years)* | 68.7 (9.8) | 70.8 (7.6) | 68.3 (8.6) | 69.3 (8.7) |
| Body mass index* | 28.1 (5.3) | 27.8 (3.0) | 28.8 (5.2) | 28.2 (4.6) |
| HLA-A2 + haplotype (n.) | 11 | 10 | 7 | 28 |
| Time since first PC diagnosis (years)* | 5.0 (4.8) | 6.8 (5.6) | 4.6 (4.5) | 5.5 (5.0) |
| Gleason score** | 8.0 (6–10) | 8.0 (6–10) | 8.0 (6–9) | 8.0 (6–10) |
| Time since CRPC diagnosis (months)* | 12.9 (7.4) | 13.1 (7.9) | 15.0 (10.2) | 13.7 (8.6) |
| Pre-docetaxel abiraterone or enzalutamide (n.) | 3 | 4 | 2 | 9 (9.2%) |
| Cumulative docetaxel dose | ||||
| 300–525 mg/m2 (n.) | 10 | 10 | 13 | 33 (33.7%) |
| 526–825 mg/m2 (n.) | 21 | 21 | 20 | 62 (63.3%) |
| > 825 mg/m2 (n.) | 1 | 2 | 0 | 3 (3.1%) |
| Time since last docetaxel infusion (weeks)* | 10.8 (5.9) | 12.5 (9.1) | 12.8 (17.2) | 12.1 (11.7) |
| Docetaxel outcome | ||||
| Response (n.) | 26 | 20 | 30 | 76 (77.6%) |
| Disease stability (n.) | 6 | 13 | 3 | 22 (22.4%) |
| Metastatic sites | ||||
| Skeletal only (n.) | 8 | 13 | 13 | 34 (34.7%) |
| Soft tissue (nodal, visceral) only (n.) | 6 | 5 | 5 | 16 (16.3%) |
| Bone and soft tissue (n.) | 18 | 14 | 15 | 47 (48.0%) |
| Serum testosterone < 1.7 nmol/L (n.) | 30 | 33 | 33 | 96 (98.0%) |
| ECOG performance status 0/1 (n.) | 24/8 | 24/9 | 20/13 | 68/30 |
*Mean (SD); **Median (range)